Target Name: PCDH11X
NCBI ID: G27328
Other Name(s): PCDH-X | PCDH11Y | Protocadherin 11 X-linked, transcript variant e | protocadherin-S | OTTHUMP00000023642 | protocadherin 11X | protocadherin 11 X-linked | Protocadherin-11 | PCDH11X variant c | Protein phosphatase 1, regulatory subunit 119 | Protocadherin-S | PCDHX | Protocadherin-11 Y-linked | Protocadherin 11X | PCDH-Y | Protocadherin-11 X-linked (isoform c) | Protocadherin-11 X-linked (isoform e) | protein phosphatase 1, regulatory subunit 119 | Protocadherin prostate cancer | Protocadherin-PC | PCDH22 | Protocadherin 11 X-linked | Protocadherin 11 X-linked, transcript variant c | PC11X_HUMAN | Protocadherin on the Y chromosome | Protocadherin on the X chromosome | protocadherin on the X chromosome | Protocadherin-11 X-linked | PCDH11X variant e | OTTHUMP00000217565 | Protocadherin-22 | PPP1R119 | PCDH11

PCDH11X: A Potential Drug Target and Biomarker for the Treatment of Psychiatric Disorders

PCDH-X, or Pyroelectric Current-Driven Hyperactivity, is a gene that has been identified as a potential drug target and biomarker for the treatment of psychiatric disorders. Studies have shown that individuals with PCDH-X mutations are more likely to develop symptoms of attention deficit hyperactivity disorder (ADHD), as well as other psychiatric disorders, such as oppositional defiant disorder (ODD) and attention deficit disorder (ADD).

The exact function of PCDH-X is not yet fully understood, but it is known to play a role in the development of disruptive behaviors. Studies have shown that individuals with PCDH-X mutations have increased activity in the prefrontal cortex, an area of the brain that is responsible for executive function and decision-making. This increased activity is thought to contribute to the symptoms of psychiatric disorders that are associated with PCDH-X.

In addition to its potential as a drug target, PCDH-X has also been identified as a potential biomarker for the treatment of psychiatric disorders. Studies have shown that individuals with PCDH-X mutations have reduced levels of a protein called serotonin, which is involved in mood regulation and other functions. This reduction in serotonin levels is thought to contribute to the symptoms of psychiatric disorders that are associated with PCDH-X.

While further research is needed to fully understand the function of PCDH-X and its potential as a drug target and biomarker, its potential as a treatment for psychiatric disorders is an exciting area of research. With further studies, it may be found that PCDH-X can be a valuable tool in the treatment of psychiatric disorders that are currently difficult to treat.

Protein Name: Protocadherin 11 X-linked

Functions: Potential calcium-dependent cell-adhesion protein

More Common Targets

PCDH11Y | PCDH12 | PCDH15 | PCDH17 | PCDH18 | PCDH19 | PCDH20 | PCDH7 | PCDH8 | PCDH9 | PCDH9-AS3 | PCDH9-AS4 | PCDHA1 | PCDHA10 | PCDHA11 | PCDHA12 | PCDHA13 | PCDHA14 | PCDHA2 | PCDHA3 | PCDHA4 | PCDHA5 | PCDHA6 | PCDHA7 | PCDHA8 | PCDHA9 | PCDHAC1 | PCDHAC2 | PCDHB1 | PCDHB10 | PCDHB11 | PCDHB12 | PCDHB13 | PCDHB14 | PCDHB15 | PCDHB16 | PCDHB17P | PCDHB18P | PCDHB19P | PCDHB2 | PCDHB3 | PCDHB4 | PCDHB5 | PCDHB6 | PCDHB7 | PCDHB8 | PCDHB9 | PCDHGA1 | PCDHGA10 | PCDHGA11 | PCDHGA12 | PCDHGA2 | PCDHGA3 | PCDHGA4 | PCDHGA5 | PCDHGA6 | PCDHGA7 | PCDHGA8 | PCDHGA9 | PCDHGB1 | PCDHGB2 | PCDHGB3 | PCDHGB4 | PCDHGB5 | PCDHGB6 | PCDHGB7 | PCDHGB8P | PCDHGC3 | PCDHGC4 | PCDHGC5 | PCED1A | PCED1B | PCED1B-AS1 | PCED1CP | PCF11 | PCF11-AS1 | PCGEM1 | PCGF1 | PCGF2 | PCGF3 | PCGF3-AS1 | PCGF5 | PCGF6 | PCID2 | PCIF1 | PCK1 | PCK2 | PCLAF | PCLO | PCM1 | PCMT1 | PCMTD1 | PCMTD1-DT | PCMTD2 | PCNA | PCNA-AS1 | PCNAP1 | PCNAP3 | PCNP | PCNPP1